Citadel Advisors’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$68M Sell
347,218
-78,018
-18% -$15.2M 0.01% 1103
2025
Q4
$73.8M Buy
425,236
+294,622
+226% +$53.6M 0.01% 1085
2025
Q3
$24.9M Buy
130,614
+102,519
+365% +$18.2M ﹤0.01% 2062
2025
Q2
$5.05M Sell
28,095
-107,948
-79% -$18.7M ﹤0.01% 4102
2025
Q1
$23M Buy
+136,043
New +$22.3M ﹤0.01% 1883
2024
Q4
Sell
-748,133
Closed -$116M 14671
2024
Q3
$116M Sell
748,133
-419,014
-36% -$62.6M 0.02% 615
2024
Q2
$160M Buy
1,167,147
+1,018,286
+684% +$139M 0.03% 438
2024
Q1
$19.8M Sell
148,861
-52,563
-26% -$6.82M ﹤0.01% 2078
2023
Q4
$27.8M Buy
201,424
+126,775
+170% +$16.7M 0.01% 1703
2023
Q3
$9.1M Sell
74,649
-52,914
-41% -$7.05M ﹤0.01% 2812
2023
Q2
$17.9M Sell
127,563
-47,950
-27% -$6.61M ﹤0.01% 1996
2023
Q1
$24.8M Buy
175,513
+153,093
+683% +$21.9M 0.01% 1715
2022
Q4
$3.51M Sell
22,420
-89,321
-80% -$12.8M ﹤0.01% 4494
2022
Q3
$13.7M Buy
111,741
+30,909
+38% +$4.07M ﹤0.01% 2339
2022
Q2
$10.7M Buy
80,832
+77,749
+2,522% +$10.6M ﹤0.01% 2591
2022
Q1
$422K Sell
3,083
-89,486
-97% -$12.5M ﹤0.01% 9782
2021
Q4
$16M Sell
92,569
-32,674
-26% -$4.97M ﹤0.01% 2314
2021
Q3
$18.2M Buy
125,243
+46,794
+60% +$6.85M ﹤0.01% 2147
2021
Q2
$10.4M Buy
78,449
+27,068
+53% +$3.54M ﹤0.01% 3015
2021
Q1
$6.59M Sell
51,381
-157,544
-75% -$19.4M ﹤0.01% 3705
2020
Q4
$24.9M Buy
208,925
+151,259
+262% +$18.4M 0.01% 1580
2020
Q3
$6.6M Sell
57,666
-1,168,807
-95% -$138M ﹤0.01% 2769
2020
Q2
$140M Buy
1,226,473
+1,201,775
+4,866% +$127M 0.05% 278
2020
Q1
$1.98M Sell
24,698
-7,396
-23% -$766K ﹤0.01% 4160
2019
Q4
$3.43M Sell
32,094
-564,944
-95% -$58.9M ﹤0.01% 3604
2019
Q3
$63.9M Buy
597,038
+482,670
+422% +$49.6M 0.03% 614
2019
Q2
$11.6M Buy
114,368
+105,802
+1,235% +$10.2M 0.01% 1994
2019
Q1
$771K Buy
8,566
+5,864
+217% +$508K ﹤0.01% 6050
2018
Q4
$225K Sell
2,702
-499,844
-99% -$46.9M ﹤0.01% 7694
2018
Q3
$54.2M Sell
502,546
-862,545
-63% -$94.6M 0.02% 713
2018
Q2
$150M Buy
1,365,091
+835,421
+158% +$87M 0.07% 235
2018
Q1
$53.1M Buy
529,670
+273,899
+107% +$28.1M 0.03% 566
2017
Q4
$25.2M Sell
255,771
-61,428
-19% -$5.82M 0.02% 1034
2017
Q3
$29.7M Buy
317,199
+299,093
+1,652% +$31.8M 0.02% 839
2017
Q2
$2.01M Buy
+18,106
New +$1.91M ﹤0.01% 3158
2016
Q4
Sell
-51,842
Closed -$4.47M 7340
2016
Q3
$4.39M Sell
51,842
-281,009
-84% -$23.6M ﹤0.01% 2113
2016
Q2
$27.1M Sell
332,851
-69,382
-17% -$5.28M 0.03% 603
2016
Q1
$28.7M Sell
402,233
-137,753
-26% -$9.24M 0.04% 553
2015
Q4
$38.4M Buy
539,986
+136,791
+34% +$9.2M 0.04% 513
2015
Q3
$24.8M Buy
403,195
+116,511
+41% +$8.14M 0.02% 760
2015
Q2
$20.8M Buy
286,684
+40,335
+16% +$2.98M 0.02% 971
2015
Q1
$18.9M Sell
246,349
-2,220,668
-90% -$159M 0.02% 1009
2014
Q4
$165M Buy
2,467,017
+2,354,964
+2,102% +$149M 0.16% 94
2014
Q3
$6.8M Sell
112,053
-410,518
-79% -$25.3M 0.01% 1704
2014
Q2
$30.7M Buy
522,571
+296,197
+131% +$17.3M 0.04% 592
2014
Q1
$13.1M Sell
226,374
-115,521
-34% -$6.19M 0.02% 1099
2013
Q4
$18.3M Buy
341,895
+305,695
+844% +$18.1M 0.02% 848
2013
Q3
$2.24M Sell
36,200
-28,521
-44% -$1.71M ﹤0.01% 2305
2013
Q2
$3.92M Buy
+64,721
New +$3.86M 0.01% 1796

Other funds holding DGX

Citadel Advisors's DGX Position: Q1 2026 in Review

Citadel Advisors reduced its Quest Diagnostics (DGX) stake by 18% in Q1 2026, selling an estimated $15.2M and leaving 347,218 shares worth $68M. The position accounts for 0.01% of the portfolio, ranked #1103.

Citadel Advisors first reported a position in DGX in Q2 2013 and has held it in 49 quarters since. The position peaked at $165M in Q4 2014. 1,063 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Citadel Advisors held 347,218 shares of Quest Diagnostics worth $68M as of Q1 2026.
  • Citadel Advisors sold 78,018 Quest Diagnostics shares in Q1 2026, an estimated $15.2M.
  • Quest Diagnostics made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1103 holding.
  • Citadel Advisors first reported a position in Quest Diagnostics in Q2 2013 and has held it in 49 quarters since.
  • Citadel Advisors's Quest Diagnostics position peaked at $165M in Q4 2014.
  • 1,063 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.